Objective : We have reported that angiotensin II AT receptors are upregulated and that there are no AT receptors in the ventricles of 1 2 cardiomyopathic hamsters. Since the upregulation was present even when no histological lesions were detectable, these results suggested that angiotensin II plays a role in the genesis / maintenance of this pathology. A survival study was conducted to compare the effects of an angiotensin II AT receptor antagonist, losartan (L), to those of a placebo (P). Since the angiotensin-converting enzyme (ACE) inhibitor 1 quinapril (Q) has been shown to have beneficial effects in this animal model, a Q group was included. Methods: Male Syrian cardiomyopathic hamsters (CHF 146, n5360) were orally administered P, low-(30 mg / kg / day) or high-dose (100 mg / kg / day) L, or Q (100 mg / kg / day), starting at day 50 of life. Inbred control hamsters (CHF 148, n5180) were treated with P or L (100 mg / kg / day) as controls. Animals were sacrificed at intervals to evaluate cardiac hypertrophy. Kaplan-Meier analysis was performed to assess differences in survival. Results: High-dose L had no effects on the survival of control hamsters. There was an unexpected dose-dependent decrease in the survival of cardiomyopathics treated with L (low-dose, P50.14; high-dose, P50.0015) compared to an increase with Q (P50.0003).
Introduction
divided into four temporal phases: prenecrotic (25-30 days), necrotic (70-75 days), hypertrophic (125-150 days) Syrian golden hamsters of the cardiomyopathic strain with progressing dilatation (225-250 days), and severe have a non-pressure-overload cardiac disease that origiheart failure (325-350 days) [3] . The clinical course and nates from a genetically transmitted metabolic anomaly pathological aspects of the hamster's chronic cardiac that induces degenerative lesions in all striated muscles, condition resemble hypertrophic cardiomyopathy observed with particular consistency and intensity in the heart [1] .
in clinics. As in humans, the resulting depression of The animals have a common defect in a gene for deltacardiac function is associated with a significant decrease in sarcoglycan, a dystrophin-associated glycoprotein, which is life expectancy. functionally involved in stabilizing sarcolemma [2] . The Compared with normal animals, it has been shown that development of the pathology is characterized by the the cardiomyopathic hamsters display an activated reninoccurrence of focal myocardial degeneration and it can be angiotensin system, which is characterized by higher plasma and ventricular angiotensin II concentrations, as well as higher ventricular angiotensin-converting enzyme (ACE) activity [4] [5] [6] . Shiota et al. [7] have also reported that heart chymase is activated in the cardiomyopathic hamster during the necrotic and hypertrophic stages. It has been demonstrated that ACE inhibitors, such as quinapril, cilazapril, imidapril, indopril, enalapril and captopril, improve myocardial collagen metabolism and decrease cardiac remodeling [8] [9] [10] , preserve contractile function [4, 5, 11] , prevent the progression of left ventricular failure and / or increase the probability of survival [4, 12, 13 ] of these animals. Many studies have demonstrated that angiotensin II, via AT receptors, stimulates myocardial cell hypertrophy as well as growth of the cardiac interstitium [4, 14] . The cardioprotective effect of chronic ACE inhibition that has been observed in several hypertrophic experimental models dividually in a temperature-controlled room, with a 6:00 [15-17] and in human progressive cardiac failure [18, 19] , a.m. to 6:00 p.m. light-dark cycle. The animals were given has been attributed to the inhibition of cardiac ACE a regular rat chow and had access to tap water ad libitum. activity and mainly to the resulting decrease in AT At 50 days of age, the hamsters were equally divided 1 receptor activation. Studies from our laboratory have (n590) and randomly assigned to one of the experimental shown significant increases in ventricular angiotensin II groups ( Fig. 1 ). AT receptor expression in cardiomyopathic hamsters, 1 whereas AT receptors have not been detected [20] . Since 2.3. Drug administration 2 the upregulation was present before the appearance of the cardiac histological lesions, this strongly suggested that the The low-dose of losartan (30 mg / kg / day) was derenin-angiotensin system and, more specifically, the AT termined as a dose that significantly shifts to the right the 1 receptors, are involved in the development and / or the angiotensin II pressor dose-response curves obtained in maintenance of the cardiomyopathy in Syrian hamsters. In anesthetized hamsters [21] . Fig. 2 presents the results this case, since it has been established that angiotensin II obtained in untreated animals as well as in treated hamsters might be produced in the heart of hamsters via alternate 24-h following oral administration of a single dose of pathways that are independent of the converting enzyme losartan (30 mg / kg). The dose-response curves were [7] , a specific blockade of AT receptors should offer statistically analyzed using AllFit for Windows [22] and 1 greater protection than the inhibition of the converting indicate a significant (P#0.001) blockade of AT re-1 enzyme. ceptors. A high-dose of losartan (100 mg / kg / day) was The first aim of this study was therefore to evaluate the administered to eliminate false negative results (data not effects of a chronic blockade of AT receptors on the 1 survival of cardiomyopathic hamsters compared with those of a placebo as well as of a chronic ACE inhibition used as a positive control. The second aim was to correlate the animals' survival with the development of the cardiac histological lesions and / or the degree of ventricular hypertrophy.
Methods

Materials
Losartan was supplied by Merck (Rahway, NJ, USA) and quinapril by Parke-Davis (Ann Arbor, MI, USA). shown). To offset the bitter taste of losartan, the powder guidelines of the Canadian Council for Animal Care and was dissolved in a flavoured commercial jelly (pH adjusted were monitored by an institutional animal care committee. to 7.5). The placebo (jelly alone) and the drug were The probability of survival of placebo-, losartan-(lowadministered orally between 8:00 and 10:00 a.m. everyday, and high-dose) and quinapril-treated hamsters was dein 200 ml aliquots using a micropipette.
Animals and experimental groups
termined using the Kaplan-Meier approach to survival The dose of quinapril (100 mg / kg / day) was chosen on distributions, the log-rank test. the basis of the results of Haleen et al. [4] who demonstrated that, at this dosage, quinapril significantly prevented the progression of left ventricular failure and 2.5. Cardiac histological lesions and hypertrophy increased the probability of survival of cardiomyopathic hamsters. The powder was dissolved and administered in As already mentioned, 12 hamsters per group were drinking water that was sweetened with a sugar alternative sacrificed at 175 days of age and 12 at 325 days of age. (1%). The concentration of the solution was determined
The animals were anesthetized with thiopental (50 mg / kg, based on a previous study in which cardiomyopathic i.p. The scores, which were attributed according to the intensisacrificed at 50 days of age for heart and body weight ty and extent of the lesions, were expressed as very slight, baseline determinations.
slight, moderate or severe. The quantification was perOf the remaining animals (66 / group), the hamsters that formed by an independent blinded pathologist (ClinTriaĺ died from non-cardiac causes (wet tail, accident, etc.) were BioRecherches, Montreal, Canada). excluded from the survival study. Based on these criteria, Cardiac hypertrophy was evaluated in 175-and 325-daythe final number of hamsters in each treatment group was old animals as the ventricle-body weight ratio. Data are as follows: 61 in the inbred controls-placebo group; 63 in presented as mean6SEM. Differences between groups the inbred controls-losartan (100 mg / kg / day) group; 65 were determined using two-way analysis of variance and in the cardiomyopathics-placebo group; 65 in the carBonferroni t-tests. The critical level of significance was set diomyopathics-losartan (30 mg / kg / day) group; 64 in the at P#0.05. cardiomyopathics-losartan (100 mg / kg / day) group and 64 in the cardiomyopathics-quinapril group.
Cardiac mortality was either spontaneous or provoked 2.6. Plasma biochemical analyses by the sacrifice of the animal when the following serious signs of distress were all present (peripheral edema, Plasma sodium, potassium, ALT (alanine transaminase) dyspnea, lethargy, coldness and water consumption #3
and creatinine concentrations were evaluated in 450-dayml / day). The decision to sacrifice an animal when it was old inbred control hamsters as well as in cardiomyopathic clear that survival was only a question of a few hours was hamsters at end-stage of failure ((450 day-old, n515 / dictated by our Deontological Committee in order to group). Routine laboratory tests were performed at Sainteeliminate unnecessary suffering. In both cases (spontaJustine Hospital. Plasma sodium and potassium concenneous or provoked), a gross necropsy was always pertrations were analyzed with selective electrodes (CX-7 formed to confirm the presence of the characteristic Analysor, Beckman). Plasma ALT activity was measured symptoms of heart failure (ascites, pleural effusion, hepatoby an enzymatic rate method using ALT reagent megaly / hepatic congestion, ventricular hypertrophy and / (Synchron CX Systems). Plasma creatinine concentrationś or dilatation). The end point of the study was the death of were determined by means of the Jaffe rate method $50% of the placebo-treated cardiomyopathic hamsters as (Synchron CX Systems). Data are presented as well as the confirmation of a significant difference between mean6SEM. Differences between groups were determined cardiomyopathic placebo-and quinapril-treated groups. All using two-way analysis of variance and Bonferroni t-tests. procedures for animal experimentation conformed to the The critical level of significance was set at P#0.05.
Hemodynamic study
As hemodynamic parameters were not monitored during the survival study, the contribution of peripheral effects of the drugs on blood pressure and heart rate is unknown. Since it is well established that cardiomyopathic hamsters have low blood pressure [24, 25] , we believed that additional preload and afterload reductions would have provided little effect. Nevertheless, in order to rule out this possibility, an a posteriori hemodynamic study was performed. To do so, 350-day-old inbred control (n514) and cardiomyopathic (n521) hamsters were equally divided and randomly assigned to one of the experimental groups:
low-dose (30 mg / kg / day) or high-dose (100 mg / kg / day) of losartan and inbred controls-placebo; inbred controls-losartan (100 quinapril (100 mg / kg / day) on the probability of survival of cardiomyopathic hamsters. Quinapril significantly lowered the risk of cardiac mg / kg / day); cardiomyopathics-placebo; cardiomyodeath by 73% (P50.0003), based on the proportional hazard model. The pathics-losartan (100 mg / kg / day) and quinapril (100 mg / low-(P50.14) and high-doses (P50.0015) of losartan decreased the life kg / day). The treatments were administered for three expectancy compared with placebo as well as with quinapril (P50.0001 weeks.
for both doses of losartan).
On study day, the hamsters were anesthetized with a mixture of ketamine / xylazine (90 and 5 mg / kg i.m., respectively) and supplemented with the anesthetic when quinapril significantly increased the life expectancy, with a required. A polyethylene catheter (PE 50) filled with median probability of survival of more than 540 days. In heparin sodium (1000 U / ml) was inserted into the right fact, when the study was stopped, 77% of the hamsters carotid artery and pushed into the aorta to continuously included in the quinapril group were still alive. An monitor the arterial blood pressure with a transducer unexpected result was that low-and high-doses of losartan connected to a blood pressure analyzer (Harvard apdecreased life expectancy when compared with the placebo paratus). At the beginning of each experiment, an average (P50.14 and P50.0015, respectively) as well as with equilibration period of 30 min was allowed to ensure quinapril (P50.0001 for both doses of losartan). The stabilization of the preparation. Systolic and diastolic resulting median probabilities of survival were of 449 days blood pressures and heart rate were then monitored. Data for the low-dose of losartan and of 433 days for the are presented as mean6SEM. Differences between groups high-dose. were determined using two-way analysis of variance and Bonferroni t-tests. The critical level of significance was set 3.2. Effect of treatments on cardiac histological lesions at P#0.05.
To explain or correlate the results obtained in the survival study, ventricular histological lesions and hy-3. Results pertrophy were evaluated. Table 1 shows the incidence and intensity of calcification and fibrosis in the septum and left 3.1. Effects of treatments on survival ventricular free walls of 325-day-old inbred control and cardiomyopathic hamsters. The survival study ran for 490 days, beginning with Myocardial calcification lesions were absent in both 50-day-old animals and ending at 540 days of age. A total groups of inbred control hamsters whereas, as expected, of 29 (six spontaneous and 23 provoked), 39 (seven the occurrence of these lesions was significantly increased spontaneous and 32 provoked), 43 (three spontaneous and in the cardiomyopathic animals. In all of the car-40 provoked) and ten (two spontaneous and eight diomyopathic groups, the severity and extent of the lesions provoked) cardiac deaths were noted in the carappear to be mainly of slight / moderate intensity, with an diomyopathic groups treated with the placebo, losartan (30 incidence independent of the treatment administered. mg / kg / day), losartan (100 mg / kg / day) or quinapril, Myocardial fibrosis was almost absent in both groups of respectively. Fig. 3 presents the probability of survival for inbred control hamsters, with the exception of one hamster the four cardiomyopathic groups only, since no cardiac in which non-significant lesions of very slight intensity deaths were observed in the inbred control groups treated were observed. As expected, the intensity and extent of with either the placebo or the high-dose of losartan.
fibrotic lesions were significantly increased in the carResults for the cardiomyopathic hamsters treated with diomyopathic animals. In all of the cardiomyopathic the placebo represent a typical survival curve for these groups, the severity of the lesions appears to be mainly of animals and correspond to a median probability of survival slight / moderate intensity, with an incidence independent of 489 days. As already reported by Haleen et al. [4] , of the treatment administered. 
. Effect of treatments on cardiac hypertrophy
the development of cardiac hypertrophy. This increase was not reversed and was even accentuated by both doses of Fig. 4 presents the body weights measured in 50-, 175-losartan. In contrast, quinapril significantly decreased the and 325-day-old animals. At 175 and 325 days of age, ventricle-body weight ratio when compared with both inbred controls presented significant increases compared losartan groups and the placebo group. with the cardiomyopathic groups. In these animals, the high-dose of losartan had no effect. Cardiac hypertrophy was determined as the ventricle-body weight ratio of 175-3.4. Plasma analyses and 325-day-old hamsters. Fig. 5 presents the values obtained at 325 days of age in both groups of animals. A Table 2 presents the plasma sodium, potassium, ALT similar pattern was already present at 175 days of age, and creatinine concentrations evaluated in 450-day-old although significance was not reached (data not shown).
inbred control hamsters and cardiomyopathic hamsters at The high-dose of losartan had no effect in inbred control end-stage of failure ((450-day-old). The high-dose of animals. As expected, a significant increase was observed losartan had no effects on these parameters in inbred in the placebo-treated cardiomyopathic group, confirming control animals. Compared with inbred control groups, significant increases in sodium, potassium and ALT concentrations were found in the cardiomyopathic group treated with the placebo, whereas no differences were noted in the creatinine concentrations. Losartan had no effects on these values, with the exception of a significant increase in creatinine concentrations related to the administration of the high dose. Quinapril significantly decreased the sodium levels and significantly increased the potassium The values are expressed as mean6SEM, n512 per group. *P,0.05 vs. inbred control animals. inbred controls, †P,0.05 vs. cardiomyopathics-placebo. interventions on the renin-angiotensin system is independent of the development and / or intensity of the primary cardiac histological lesions. This strongly suggests that the and creatinine concentrations. These drug-induced changes role of the renin-angiotensin system in the progression of were not related to the progression of cardiac hypertrophy the cardiomyopathy is more likely that of an adaptive or to life expectancy.
process rather than a causative mechanism involved in the genesis of the pathology.
Pressor and chronotropic effects of treatments
Hemodynamic parameters were not evaluated during the survival study and, therefore, the contribution of peripheral Table 3 presents the hemodynamic parameters detereffects of the drugs on blood pressure and heart rate is mined in an a posteriori study using 350-day-old anesunknown. Nevertheless, the very low systolic and diastolic thetized hamsters following 2262 days of treatment. As blood pressures of the cardiomyopathic hamsters, as well expected, significant decreases were observed in systolic as the lack of hemodynamic effects of losartan or quinapril and diastolic blood pressures of cardiomyopathic hamsters that were determined in the a posteriori study, strongly compared with the values noted in inbred control animals. support the conclusion that preload and afterload reducLosartan or quinapril had no effect on blood pressure in tions have played minor roles, if any, in the overall effects either groups of hamsters. No differences were noted in of the different treatments. While there is no definitive heart rate between the inbred control and cardiomyopathic explanation for interpreting our results, they do suggest the animals and, again, no differences were observed with the following hypotheses: (1) the cardioprotective effect of administration of losartan or quinapril.
quinapril is related to the blockade of the renin-angiotensin system as well as to the accumulation of endogenous kinins and, more specifically, of bradykinin; (2) the 4. Discussion beneficial effects of the AT receptor antagonists already 1 reported using other experimental models are related to the Our results demonstrate that chronic blockade of AT blockade of AT receptors but also to the activation of 1 1 receptors is associated with a significant reduction in the AT receptors and (3) in this experimental model, the 2 upregulation of AT receptors is an adaptative phenom-1 Table 3 enon and, in this case, the inotropic effect of angiotensin II Pressor and chronotropic effects of losartan and quinapril in 350-day-old is essential to support the failing heart. inbred control and cardiomyopathic hamsters (treatment duration52262
Beneficial effects in experimental models of heart failure days)
have been described with the administration of ACE and an increase in survival with captopril, enalapril and Haleen et al. [4] . In their study, the treatment was started in 180-day-old CHF 146 hamsters and quinapril (100 cellular proliferation has been observed using coronary mg / kg / day) increased the median probability of survival endothelial cells [34] , vascular smooth muscle cells [35] as of the animals by 33% compared with the untreated group. well as cardiomyocytes [36] . It has been suggested by The major effect on survival occurred during the first 210 Masaki et al. [37] that AT receptors have an anti-AT 2 1 days of treatment and, thereafter, the mortality rate of the effect on cell proliferation and may play a role in developgroups was comparable. In our study, the improvement in ment and / or differentiation. life expectancy (↓73% in risk of cardiac death, P50.0003)
The level of expression of AT receptors is generally 2 related to quinapril was greater and more sustained, with low in the adult cardiovascular system and the involvement 77% of the hamsters included in this group still alive at the of these receptors in the progression of heart failure is end of the study. This greater effect is certainly related to presently highly speculative. Nevertheless, since their the fact that quinapril was started in younger animals expression is increased in remodeling hearts, such as in (50-day-old) before the appearance of cardiac histological cardiac hypertrophy and infarction [38, 39] , and since the lesions and the development of hypertrophy.
AT -AT ratio is increased in failing human hearts 2 1 In the study by Haleen et al. [4] , the improved survival [40, 41] [20] . It is therefore tempting cardiac remodeling process. This possibility is further to postulate that the lack of influence of AT receptor 1 strengthened by the fact that the harmful effect observed blockade on ventricular hypertrophy as well as the negafollowing AT receptor blockade was related to the tive effect on survival observed in cardiomyopathic ham-1 absence of effects and even to an increase in the developsters were related, at least in part, to the absence of AT 2 ment of cardiac hypertrophy.
receptor activation and, thereby, of their resulting antiThe mechanism(s) by which quinapril decreased the proliferative effect. development of cardiac hypertrophy is(are) still unclear.
In the last two decades, it has become evident that One of the most common hypotheses is that the beneficial tissular renin-angiotensin systems exist, including in the effects of ACE inhibitors may result not only from a myocardium [42] . It is now acknowledged that locally reduced angiotensin II-AT receptor interaction but also produced angiotensin II may act either in an autocrine or a 1 from bradykinin potentiation [29] . Studies by Bao et al. paracrine fashion to directly modulate cardiac function [30] as well as by Linz and Scholkens [31] have shown through a mechanism that is independent of its peripheral that ventricular hypertrophy induced in spontaneous and action [43, 44] . Despite an apparent lack of inotropic aortic-banded hypertensive rats is reduced by treatment response to angiotensin II in the myocardium of the guinea with the ACE inhibitor, ramipril. In these models, the pig and the adult rat, a positive inotropic response to regression of cardiac hypertrophy was abrogated by the angiotensin II has been demonstrated in cardiac muscle concomitant administration of HOE-140, a highly potent from several species, such as the cat, rabbit, calf and bradykinin B receptor antagonist. Similar results have chicken, and in isolated perfused hearts from normal and 2 also been obtained by McDonald et al. [32] using a model cardiomyopathic hamsters [45, 46] . It has also been reof ventricular remodeling induced by transmyocardial ported that angiotensin II exerts positive inotropic effects direct current shock in dogs, as well as by Liu et al. [33] in human atrial preparations but not in right or left using a model of heart failure induced by coronary ligation ventricular preparations [47] . When present, physiological in rats. Altogether, these results support the hypothesis that studies with specific AT antagonists have proven that the 1 the accumulation of endogenous bradykinin, resulting from inotropic effect of angiotensin II is mediated by AT 1 ACE inhibition, plays a role in the benefit of this therapy receptors [48, 49] . The contribution of angiotensin II to the in the case of progressive heart failure and, more parmaintenance of the contractile status of a physiological ticularly, in the cardioprotective effect that we and others and / or pathological heart is still however not known. have observed in the cardiomyopathic hamster.
Nevertheless, it may be hypothesized that the upregulation Treatment with AT antagonists causes elevation of of AT receptors observed in the cardiomyopathic hamster 1 1 plasma angiotensin II, which may selectively bind to heart represents an adaptative mechanism that compensates unblocked AT receptors. So far, the roles of AT refor the altered contractility and the development of cardiac 2 2 ceptors in physiopathology have not been clarified. Howdysfunction that is secondary to the primary genetic ever, until now, an inhibitory effect of these receptors on defects. In such a case, the complete inhibition of AT 1
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receptors would be detrimental, especially for the failing heart failure models.
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